Quercetin in COVID19

Evaluation of the effect of quercetin on the effectiveness of antiviral drug regimen in patients with COVID19

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200419047128N2

Enrollment

Registered

2020-04-24

Start date

2020-04-29

Completion date

Unknown

Last updated

2021-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID19. Corona virus infection, unspecified

Interventions

Intervention 1: Intervention group: 2 Tabs Quercetin(500mg) from Jarrow Formulas , daily until 7 days. Both case and control group will be received routine drugs. Intervention 2: Control group: this g

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Polymerase chain reaction (PCR) confirmed infection with COVID19 Lung involvement confirmed with chest imaging Hospitalized with: Fever (axillar or oral temperature = 38.0 °centigrade(C) or =38.6°centigrade tympanic or rectal) Or Cough Willingness of study participant to accept randomization to any assigned treatment arm Acceptance of non-participation in another study before the 28th day of the study

Exclusion criteria

Exclusion criteria: Autoimmune diseases (lupus, MS, etc.) Hepatic failure Hepatit B, C, pregnant and lactating women Not consent to participate in the study

Design outcomes

Primary

Measure	Time frame
Viral diagnostic test. Timepoint: The first day of the study and the end of the study (14th). Method of measurement: Polymerase chain reaction.	—

Secondary

Measure	Time frame
Blood oxygen saturation percentage. Timepoint: Before and-4-7 days after starting treatment. Method of measurement: Pulse oximeter.;Cough rate. Timepoint: Before and 7 days after starting treatment. Method of measurement: Physical examination.;C-Reactive Protein (CRP). Timepoint: Before and 7 days after starting treatment. Method of measurement: ?ELISA (enzyme-linked immunosorbent assay).;IL1. Timepoint: Before and 7 days after starting treatment. Method of measurement: ELISA (enzyme-linked immunosorbent assay).;IL6. Timepoint: Before and 7 days after starting treatment. Method of measurement: ELISA (enzyme-linked immunosorbent assay).;CBC. Timepoint: Before and 7 days after starting treatment. Method of measurement: Cell Counter.	—

Measure

Time frame

Blood oxygen saturation percentage. Timepoint: Before and-4-7 days after starting treatment. Method of measurement: Pulse oximeter.;Cough rate. Timepoint: Before and 7 days after starting treatment. Method of measurement: Physical examination.;C-Reactive Protein (CRP). Timepoint: Before and 7 days after starting treatment. Method of measurement: ?ELISA (enzyme-linked immunosorbent assay).;IL1. Timepoint: Before and 7 days after starting treatment. Method of measurement: ELISA (enzyme-linked immunosorbent assay).;IL6. Timepoint: Before and 7 days after starting treatment. Method of measurement: ELISA (enzyme-linked immunosorbent assay).;CBC. Timepoint: Before and 7 days after starting treatment. Method of measurement: Cell Counter.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli khodadadi

Ahvaz University of Medical Sciences

akhodadadi2@gmail.com+98 61 3333 7446

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026